Weight-loss jabs are only half the treatment. The other half is missing
As Chair of the APPG on Obesity, Mary Glindon MP argues that the support meant to go alongside weight-loss medication is too often absent, leaving people to manage alone.
Weight-loss medication has moved from the margins to the mainstream remarkably quickly. According to the Food Foundation, around 7% of UK adults have now used a GLP-1 medicine such as Mounjaro or Wegovy, and the vast majority do so through private prescriptions rather than the NHS.
For many people these medicines have made a real difference, and I welcome that. But a prescription was never meant to be the whole treatment. NICE is clear that people using these medicines should receive behavioural support covering diet, nutrition and physical activity, and that people coming off them should be supported for at least a year afterwards.
The reality falls well short. Last month the Health and Social Care Committee found that dietary and exercise support is not widely available across the country. On the NHS, what you get depends heavily on where you live, and the picture can be just as varied for people accessing medication privately, with the support on offer differing from one provider to the next.
This matters because medication alone does not teach anyone how to eat well on smaller portions, build activity into their week or change habits formed over decades. The evidence on what happens next is clear. Research published in the BMJ this year found that people regain weight faster after stopping weight-loss medication than after finishing a behavioural weight management programme. Without support, we risk spending a great deal of public and private money on results that do not last.
The public understands this. New YouGov polling for Slimming World found that 71% of UK adults would expect someone they know who was prescribed weight-loss medication to receive regular lifestyle support throughout treatment. Around three-quarters say that support is just as important (58%), or more important (18%), for people on medication. Only 6% think it matters less.
Yet the same polling shows how easily people slip through the gap. When asked about reasons for stopping or delaying support outside of weight-loss medication and treatment, 13% would simply assume they did not need it, and 16% say they would not know where to find it. Further reasons include cost which would stop or delay almost a third of adults from seeking support (31%), rising to 44% among people who have used these medicines. Leaving people to find and fund their own support means those with the least are the most likely to go without.
Stigma makes this harder still. Only half of adults (52%) would tell their GP if they had been prescribed weight-loss medication elsewhere, and one in eight (12%) would tell no one at all. Fear of judgement (30%) and unwanted comments (31%) are among the main reasons for feeling uncomfortable disclosing the personal use of weight-loss medication. This suggests that if people feel they have to keep their treatment quiet, they are unlikely to ask for help from the professionals best placed to give it.
None of this needs new guidance, because the standard already exists. What is missing is a system that delivers it consistently. I want to see three things.
First, behavioural support should come as standard with every prescription, with the same standards applying whether it is issued by the NHS or a private provider. Second, support should last for the length of treatment and beyond it, with commissioning cycles long enough to make that possible. Third, primary care should be equipped to have non-judgemental conversations about weight and to refer people on, since the GP is still where most people would turn first.
The Committee has called for weight management services to be overhauled, and the Government’s response is a chance to close this gap before it widens further. Millions of people have already taken a step to improve their health. They deserve the support to make it last.
Mary Glindon is Labour MP for Newcastle upon Tyne East and Wallsend and Chair of the APPG on Obesity.
All figures, unless otherwise stated, are from YouGov Plc. Total sample size was 2,130 adults. Fieldwork was undertaken between 15th and 16th October 2026. The survey was carried out online. The figures have been weighted and are representative of all UK adults (aged 18+).